WASHINGTON — The Food and Drug Administration has approved Novo Nordisk’s Wegovy pill, the first oral GLP-1 weight-loss drug cleared in the United States, offering a once-daily option for adults with obesity or overweight and at least one weight-related condition, Dec. 22, 2025. The decision could widen access for people who avoid injections and accelerate a shift toward easier-to-distribute obesity medicines, according to company and market reporting.
Novo Nordisk said the Wegovy pill is an oral form of semaglutide at a 25 mg dose and is approved for long-term weight management and to reduce the risk of major adverse cardiovascular events in certain patients. The company also said it expects the product to launch in the U.S. in early January, positioning it ahead of rival oral candidates still moving through late-stage trials and review (Novo Nordisk’s announcement).
What the Wegovy pill approval changes
GLP-1 medicines have reshaped obesity treatment, but most blockbuster options have required injections. The Wegovy pill brings the category into a more familiar format for patients and could ease supply constraints over time because pills are generally simpler to manufacture, ship and store than injectable pens. Reuters noted that the move gives Novo Nordisk an early lead in what many analysts see as the next competitive front in obesity care (Reuters analysis).
In pivotal testing referenced in industry coverage, people taking oral semaglutide at the highest dose lost around the mid-teens percentage of body weight over about 64 weeks, with gastrointestinal side effects similar to injectable GLP-1s. Scientific American described the decision as potentially “transformative” for care delivery because the oral option could broaden uptake among patients who have been reluctant to start injections. Time reported trial results in the same range and emphasized the convenience factor for daily dosing.
How to take the Wegovy pill
Like other oral semaglutide products, dosing instructions can matter. Some GLP-1 tablets are taken on an empty stomach with limited water, then followed by a waiting period before eating, a routine designed to help absorption. Patients prescribed the Wegovy pill should follow the FDA-approved label and their clinician’s guidance—especially if they take other morning medications.
Why the Wegovy pill matters in a longer timeline
The approval builds on years of semaglutide expansion. Novo Nordisk’s original Wegovy injection won FDA clearance for chronic weight management in 2021, setting up the modern GLP-1 obesity boom (2021 Wegovy approval release). In 2024, the FDA expanded Wegovy’s label to include cardiovascular risk reduction in certain patients with obesity or overweight and established heart disease (FDA press announcement).
The path to an obesity-focused tablet also traces back to 2019, when the FDA approved Rybelsus as the first oral GLP-1 for Type 2 diabetes, proving that a pill-based semaglutide could work clinically, even if higher doses were needed for weight loss (2019 Rybelsus approval release).
For patients, the Wegovy pill adds another choice rather than replacing injections outright. For prescribers, it opens a new conversation about adherence, side effects, and insurance coverage—especially as more oral GLP-1 and incretin pills approach the market. Either way, the Wegovy pill marks a milestone: the first time U.S. regulators have endorsed a GLP-1 tablet specifically for weight loss.
